new glp-1 receptor agonists as Treatments for Type 2 Diabetes GLP-1 Receptor Agonist Market Size

The question remains: are we witnessing the peak of obesity-driven M&A, or is this just the beginning of a decade-long race for dominance

And I think youve even told the story of the Gila monsters, and well get to that in a second

Patients are looking for weight loss care that is convenient, medically guided, and easier to understand, said Luke Battiloro, spokesperson for DietsMD.com

In the IMPACT trial, pemvidutide achieved mean weight losses of 4.8% and 5.8% with 1.2 and 1.8 mg doses respectively at 24 weeks, compared to 0.5% with placebo, with weight loss curves showing no evidence of plateauing, suggesting continued benefit with longer treatment [49-51]